Balyasny Asset Management
ABEO icon

Balyasny Asset Management’s Abeona Therapeutics ABEO Stock Holding History

Balyasny Asset Management’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.64M Sell
589,847
-1,890
-0.3% -$9.45K ﹤0.01% 1664
2025
Q4 		$3.12M Buy
+591,737
New +$2.98M ﹤0.01% 1647
2025
Q2 		– Sell
-73,849
Closed -$352K – 2740
2025
Q1 		$352K Buy
73,849
+39,721
+116% +$216K ﹤0.01% 2393
2024
Q4 		$190K Buy
+34,128
New +$210K ﹤0.01% 2535
2024
Q2 		– Sell
-19,026
Closed -$138K – 2504
2024
Q1 		$138K Buy
+19,026
New +$121K ﹤0.01% 2469
2018
Q4 		– Sell
-1,609
Closed -$515K – 1347
2018
Q3 		$515K Buy
1,609
+709
+79% +$252K ﹤0.01% 1371
2018
Q2 		$360K Buy
+900
New +$393K ﹤0.01% 1452
2018
Q1 		– Sell
-8,000
Closed -$3.17M – 1889
2017
Q4 		$3.17M Buy
+8,000
New +$3.31M 0.01% 1003

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Balyasny Asset Management's ABEO Position: Q1 2026 in Review

Balyasny Asset Management reduced its Abeona Therapeutics (ABEO) stake by 0.32% in Q1 2026, selling an estimated $9.45K and leaving 589,847 shares worth $2.64M. The position accounts for ﹤0.01% of the portfolio, ranked #1664.

Balyasny Asset Management first reported a position in ABEO in Q4 2017 and has held it in 8 quarters since. The position peaked at $3.17M in Q4 2017. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Balyasny Asset Management held 589,847 shares of Abeona Therapeutics worth $2.64M as of Q1 2026.
  • Balyasny Asset Management sold 1,890 Abeona Therapeutics shares in Q1 2026, an estimated $9.45K.
  • Abeona Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1664 holding.
  • Balyasny Asset Management first reported a position in Abeona Therapeutics in Q4 2017 and has held it in 8 quarters since.
  • Balyasny Asset Management's Abeona Therapeutics position peaked at $3.17M in Q4 2017.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.